HomeNews & TopicsPublic HealthAn approach to managing shortages of critical drugs during COVID-19

An approach to managing shortages of critical drugs during COVID-19

Published on

The COVID-19 pandemic has resulted in shortages of tocilizumab, a drug used to treat the disease in patients admitted to hospital, owing to high demand and limited supply. The authors of an Analysis article in CMAJ (Canadian Medical Association Journal) propose a 3-stage framework to help manage this shortage and potential future shortages.

“Health systems can rapidly respond to shortages of essential medications by estimating the clinical demand, assessing drug supply and potential inequities in access, and enacting policies grounded in an ethical framework for drug allocation,” writes Dr. Amol Verma, St. Michael’s Hospital, Unity Health Toronto, and the University of Toronto, with coauthors.

Tocilizumab, an anti-inflammatory medication used to treat rheumatoid arthritis or immune responses in people undergoing some types of cancer therapy, was discovered to be effective in treating people in hospital with severe COVID-19. It is manufactured by only one company and is in high demand worldwide. It is one of only two therapies demonstrated to save lives in patients with severe COVID-19.

The authors estimate that for every 1,000 adults hospitalized with COVID-19, more than 400 would be eligible for treatment with tocilizumab, which could potentially prevent 17 people from dying and 12 people from being ventilated.

To distribute resources during the pandemic, they propose a 3-stage approach based on 7 guiding ethical principles (beneficence, equity, reciprocity, solidarity, stewardship, trust, and utility):

  • Stage 1 – treat as many people as possible by conserving and sharing drug supply and increasing procurement and/or access.
  • Stage 2 – direct supply to people most likely to benefit based on current evidence.
  • Stage 3 – If Stage 1 and 2 efforts cannot meet demand, Stage 3 involves using a fair procedure to choose between patients, such as a lottery system, to ensure that distribution of scarce resources does not worsen existing inequities.

The authors state that “tocilizumab is in short supply and demand for the drug may increase. There is a risk of suboptimal and inequitable distribution of this scarce resource if a dedicated system-wide procurement and allocation effort is not made. The 3 stages described above could be put into operation within health systems to manage tocilizumab supply.”

They conclude that “lessons from responding to this drug shortage can inform other unexpected disruptions in drug supply and future pandemic preparedness.”

Managing drug shortages during a pandemic: tocilizumab and COVID-19” was published May 5, 2021.

Latest articles

Common drug interactions with over-the-counter medications

TJ, a 45-year-old male with symptoms of a common cold (sore throat, headache, runny...

Easing the Transition to the Cloud. Modernizing made simple with integration support.

Across Canada, most hospitals and healthcare authorities recognize the need to modernize their systems....

Rovolutionizing geriatric care: Meet Canada’s leading Universal Health Hub (UHH)

Universal Health Hub (UHH) is the only Health Care Organization in Canada which is...

National efforts to guide safe, effective, and equitable use of opioids for quality pain management in children

No one should experience untreated pain. Yet, in Canada, two out of three children...

More like this

Wait times in healthcare often linked to diagnostic testing – adding more doctors and nurses alone won’t improve that bottleneck

There is an emerging consensus that Canada’s healthcare system is in crisis.  Stories appear in...

No longer just tobacco and opioids: B.C. plans commencing more class actions to recover health care costs involving virtually any product

On March 14, 2024, the province of British Columbia proposed broad multi-government class action...

Protecting patients and the planet from unnecessary tests

Climate change is a universal problem that impacts both environmental and human health. In...

We need health system solutions now: CMA, CFPC

Medical organizations call on governments to reimagine primary care to help stabilize, rebuild health...

Wait times in EDs are nothing new – and that’s the problem

The respiratory virus season is upon us, and those working in the emergency departments...

Ontario hospitals play critical role in Canadian health care advancements and innovation

Twenty Ontario research hospitals have been celebrated for their excellence in health research and...